referby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Dated: January 30, 2007

Signature:

Docket No.: 30847/2051-004

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Anna Helgadottir et al.

Application No.: 10/769,744

Confirmation No.: 6429

Filed: January 30, 2004

Art Unit: 1634

For:

SUSCEPTIBILITY GENE FOR

Examiner: D. Johannsen

MYOCARDIAL INFARCTION, STROKE, AND PAOD; METHODS OF TREATMENT

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of documents B52 and C126-C133 are submitted herewith.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art."

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Accordingly, no fee is due. The Director Application No.: 10/769,744 Docket No.: 30847/2051-004

is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30847/2051-004. A duplicate copy of this paper is enclosed.

Dated: January 30, 2007

Respectfully submitted,

Jeanne M. Brashear

Registration No.: 56,301

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicant

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/769,744-Conf. #6429 Application Number January 30, 2004 INFORMATION DISCLOSURE Filing Date Anna Helgadottir STATEMENT BY APPLICANT First Named Inventor 1634 Art Unit (Use as many sheets as necessary) D. Johannsen Examiner Name 30847/2051-004 Attorney Docket Number 1 of

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1		Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code³-Number⁴-Kind Code⁵ (if known)	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
	B52	WO-WO 99/52942	10-21-1999	Genset				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if Enolish language Translation is attached. possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examin er	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city	T ²
Initials	C126	BATKAI et al., "Inhibition of 4-lipoxygenase Improves Regional Myocardial Function After BATKAI et al., "Inhibition of 4-lipoxygenase Improves Regional Myocardial Function After Springer Verlag, 430(4):R18 (1995).	
	C127	DIB et al., Nature, A Comprehensive Genetic Map of the Human Genome Based on 9,25. Microspatallites " vol 380, no. 6570, pages 152-154 (1996).	
	C128	European Search Report for EP 03 78 3063 dated July 18, 2006.	_
	C129	GENBANK Accession No. Z52271.	-
	C130	704270	-
	C131	GENBANK Accession number 224370. HATZELMANN et al., Inversely-correlated Inhibition of Human 5-lipoxygenase Activity by BAY X1005 and Other Quinoline Derivatives in Intact Cells and a Cell-Free System: Implications for the Function of 5-lipoxygenase Activating Protein," Biochemical Pharmacology, 47:2259-2268	
	C132	(1994). KOSHINO et al., "Novel Polymorphism of the 5-lipoxygenase Activating Protein (FLAP) Promoter Gene Associated with Asthma," Molecular Cell Biology Research Communiciations, 2:32-35 (1999).	
	C133	2:32-35 (1999). YANDAVA et al., "Cytogenetic and Radiation Hybrid Mapping of Human Arachidonate 5- lipoxygenase-activating Protein (ALOX5AP) to Chromosome 13q12," Genmoics, 56:131-133 (1999).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Date
Examiner	Considered
Signature	

1

Sheet

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.